Dermatology Company Announces First Patient Enrollment In Netherton Syndrome Trial

Azitra, Inc., a company specializing in precision dermatology, has recently announced a significant milestone in the development of ATR-12, its lead therapeutic candidate aimed at treating Netherton syndrome, a rare and severe genetic skin disorder. The company has successfully screened the first patient in its Phase 1b clinical trial, marking a crucial step forward in evaluating the potential of ATR-12 in addressing this debilitating condition. $Azitra (AZTR.US)$